Physician profile
Adel S Haque
NPI 1760913511
$1,008,382.65
in general payments reported to CMS, 2019-2025
36 companies · $524K in 2025
The $524K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $17.99 · 2021: $455 · 2022: $18K · 2023: $173K · 2024: $292K · 2025: $524K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $788K · Consulting Fee: $57K · Honoraria: $55K · Travel and Lodging: $46K · Food and Beverage: $29K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $787,858.00 |
| Consulting Fee | $57,490.75 |
| Honoraria | $55,200.00 |
| Travel and Lodging | $45,540.86 |
| Food and Beverage | $28,940.54 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $14,440.00 |
| Education | $171.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $160,991.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $149,065.18 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $130,372.37 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $110,762.06 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Galderma Laboratories, L.P. | $86,184.60 | 2022-2025 | Nemluvio, Aklief |
| Botanix Sb INC | $78,482.31 | 2025 | Sofdra |
| Amgen INC. | $66,455.38 | 2022-2025 | Otezla, Otezla |
| Organon LLC | $61,528.86 | 2024-2025 | Vtama |
| Ucb, INC. | $51,053.05 | 2022-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $50,124.43 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $24,353.41 | 2021-2025 | |
| Eli Lilly and Company | $10,959.12 | 2025 | Ebglyss |
| Incyte Corporation | $10,740.63 | 2021-2025 | Opzelura, Opzelura |
| Dermavant Sciences, INC. | $9,162.46 | 2023-2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $3,976.77 | 2022-2025 | Sotyktu |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adel Haque listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.